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Abstract
The Metabochip is a custom genotyping array designed for replication and fine mapping of metabolic, cardiovascular, and
anthropometric trait loci and includes low frequency variation content identified from the 1000 Genomes Project. It has
196,725 SNPs concentrated in 257 genomic regions. We evaluated the Metabochip in 5,863 African Americans; 89% of all
SNPs passed rigorous quality control with a call rate of 99.9%. Two examples illustrate the value of fine mapping with the
Metabochip in African-ancestry populations. At CELSR2/PSRC1/SORT1, we found the strongest associated SNP for LDL-C to
be rs12740374 (p=3.5610
211), a SNP indistinguishable from multiple SNPs in European ancestry samples due to high
correlation. Its distinct signal supports functional studies elsewhere suggesting a causal role in LDL-C. At CETP we found
rs17231520, with risk allele frequency 0.07 in African Americans, to be associated with HDL-C (p=7.2610
236). This variant is
very rare in Europeans and not tagged in common GWAS arrays, but was identified as associated with HDL-C in African
Americans in a single-gene study. Our results, one narrowing the risk interval and the other revealing an associated variant
not found in Europeans, demonstrate the advantages of high-density genotyping of common and rare variation for fine
mapping of trait loci in African American samples.
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A half-decade of successes from Genome-Wide Association
Studies (GWAS) have identified more than 1,200 SNPs associated
with 210 complex human traits [1]. While GWA studies have
produced novel genotype-phenotype associations, such studies are
but initial steps in the process of understanding the biology
relevant to human disease. Post-GWAS studies are necessary to
identify risk or causal variants given that most GWAS findings
reflect common variants, targeted for genotyping, that presumably
are in linkage disequilibrium with the actual causal variants.
A common post-GWA study design involves fine mapping a
region of interest with dense genotyping or sequencing. Fine
mapping in diverse populations has the advantage that linkage
disequilibrium architectures vary across populations, potentially
narrowing the region of interest containing the putative causal
variant [2,3]. Fine mapping in an alternate population can also
identify additional causal variants that are absent or rare in the
discovery population.
Custom genotyping arrays such as the Metabochip, an array
based on the Illumina iSelect platform, represent an attractive
approach for multi-locus fine mapping. Containing 196,725 SNPs,
including content on less common variation from the 1000
Genomes Project [4], the Metabochip was developed for
replication and fine mapping of susceptibility loci associated with
one or more metabolic and cardiovascular traits. It costs
substantially less than leading GWAS arrays or sequencing
technologies but enables analysis of low-frequency variants at fine
mapped loci. Sanna et al recently explored its use, along with
sequencing, to increase the explained heritability of LDL-C in
seven genes, including SORT1, in a Sardinian sample [5].
Although the Metabochip is specifically designed for metabolic
and cardiovascular trait association, similar custom arrays
targeting cancer and immune disease-related phenotypes are in
early use [6,7]. The performance of such arrays in non-European-
descent populations is not known, although the use of these custom
arrays in ancestrally diverse populations allows for the potential
narrowing of risk intervals in susceptibility loci uncovered by
GWAS, the discovery of low frequency susceptibility variants, and
the identification of additional independent signals in known loci.
The ‘‘Population Architecture using Genomics and Epidemiol-
ogy’’ (PAGE) study [8] recently undertook a pilot study with the
Metabochip in African Americans to facilitate fine mapping
around key GWAS loci, addressing the major goal of PAGE, the
assessment of how GWAS-identified variants generalize across
populations. In the present work, we describe the performance of
the Metabochip in African American individuals from the PAGE
study. We give two examples of the benefit this array in an African
American sample by fine mapping two established loci for serum
levels of lipids, namely the low-density lipoprotein cholesterol
(LDL-C) locus at CELSR2/PSRC1/SORT1 and the high-density
lipoprotein cholesterol (HDL-C) locus at CETP using the
Metabochip in this African American population. The examples
illustrate two types of results that can be expected by fine mapping
in African Americans: narrowing of the risk interval and discovery
of a population-specific variant. On the basis of the results
presented here PAGE has decided to use the Metabochip as its
primary genotyping platform for the immediate future.
Results
Quality Control
We genotyped a total of 6,241 African American individuals
previously recruited to 3 cohort studies: the Atherosclerosis Risk in
Communities Study (ARIC) [9], the Multiethnic Cohort (MEC)
[10], and the Women’s Health Initiative (WHI) [11]. We removed
0.9% of the samples for sample QC reasons and 5.2% of the
samples as representing half of a first-degree relative pair, leaving
5,863 unique individuals. Details are shown in Supporting
Information Table S1.
Before SNP quality control, the overall call rates were 98.98%,
97.74%, and 97.70% for ARIC, MEC, and WHI, respectively.
We summarize the SNP QC results in Supporting Information
Table S2. We considered a total of 14,328 (7.3%) variants as
technical failures because of the GenCall or cluster separation
score, call rate, Mendelian error rate, replication error rate, or
deviation from Hardy Weinberg equilibrium. There were an
additional 5,248 (2.7%) SNPs that were failed, despite passing
technical QC, because the probe sequence matched poorly to the
reference genome (no or more than one match found in reference;
probe sequence differed from reference; neither SNP allele
matched reference; a second, equally good, match to a random
contig, in addition to stated position; one or more second-best hits
in the reference that differ only by a single base). We found that
the discordance between calls by GenCall and GenoSNP, an
alternative sample-based genotype calling program [12], was low
(0.1% of genotypes; 0.8% of SNPs exceeded the QC threshold for
discordance, but 1.2% of SNPs with MAF less than 0.01 did so), as
was the discordance in YRI samples with HapMap database
genotypes for the 105,722 SNPs in common (0.3% of genotypes;
1.1% of overlapping SNPs exceeded the QC threshold for
discordance). SNPs with excessive discordance of either type were
failed (Supporting Information Table S3). An additional 6.8% of
SNPs were monomorphic across all three PAGE cohorts. Overall,
161,098 (81.9%) SNPs on the Metabochip passed our quality
control criteria and were polymorphic. The call rate for SNPs
passing QC was 99.9%. The QC profile of SNPs identified via the
1000 Genomes Project did not appreciably differ from other SNPs
with one exception: 99.4% of the monomorphic SNPs were from
the 1000 Genomes Project.
Characteristics and Distribution of Allele Frequencies
The Metabochip differs from most GWAS arrays in its coverage
of rare and low frequency variants. Figure 1 shows the percentage
of SNPs at various minor allele frequencies (MAFs) for the African
American PAGE study samples genotyped on the Metabochip
compared to HapMap ASW samples genotyped on the Affymetrix
6.0 and the Illumina 1 M arrays. A total of 21.6% of the
polymorphic Metabochip SNPs have MAF less than 0.025,
compared to 5.8% and 6.8% for the Affymetrix 6.0 and Illumina
1 M arrays, respectively. Differences between frequencies in the
Metabochip and GWAS chips are also notable in European and
European-descent populations (Figure 2) particularly for SNPs
with MAF of less than or equal to 0.001. The proportion of SNPs
passing QC across MAFs ranged from 85% to 92% with no trend
by MAF (Supporting Information Table S4).
Fine mapping in Metabochip: LDL-C case study
As an illustration of the advantages of the Metabochip in fine
mapping signals from European-descent GWAS using African-
descent individuals, we compared the region of our most
significant association with LDL-C in the PAGE African American
participants with the same region in a GWAS meta-analysis of
lipid associations in over 100,000 individuals of European ancestry
[13]. (A comprehensive analysis of lipids associations from the
Metabochip in this sample and others is described in Wu et al,i n
preparation.) In this region, as well as the region discussed below,
most of the Metabochip SNPs are poorly tagged by a GWAS
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2 less than 0.5
with SNPs on the Illumina 1 M array (Table 1). Our most
significant result for LDL-C was at SNP rs12740374 on
chromosome 1p13 at the CELSR2/PSRC1/SORT1 locus, with a
p-value of 3.48610
211. The estimated effect at this locus is a mean
increase, for each A allele, of 6.5 mg/dl of LDL-C (95% CI: 4.6 to
8.5) with a heterogeneity I
2 of 31% (considered low to moderate
[14]) and mean allele frequency of 0.25. Association of this SNP
with LDL-C was identified previously in European-ancestry
individuals [15] and in African American individuals [16]. (The
latter study included most of the ARIC sample analyzed here.) In
this region, Teslovich and colleagues [13] reported the strongest
LDL-C association at the nearby SNP rs629301 with an effect size
of 5.6 mg/dl. Figure 3A shows the Teslovich et al results in this
region.
Figure 3B demonstrates the pattern of association in this region
using the PAGE Metabochip results and showing the strength of
LD in the African American sample relative to our most significant
SNP, rs12740374. For comparison, the same results are re-plotted
in Figure 3C with LD shown from a sample of European-descent
individuals based in Malmo ¨, Sweden. Of note, with the Malmo ¨
LD there are eight SNPs that have an r
2.0.9 with the rs12740374
index SNP. Although rs629301 did not pass QC in the Malmo ¨
study, the 1000 Genomes Project [4] data shows that rs629301
and rs12740374 have r
2=1.0 in CEU. In contrast, when
examining the LD based on the PAGE African American sample,
there was only one SNP (rs7528419) with an r
2 value greater than
0.9 with rs12740374. The next five most correlated SNPs,
including rs629301, had r
2 values between 0.60 and 0.62.
Fine mapping in Metabochip: HDL-C case study
A second illustration of the use of the Metabochip in fine
mapping is at CETP on chromosome 16q21 (Figure 4), the
location of our most significant SNP associations for HDL-C in the
PAGE African American samples at rs17231520 (p=7.2610
236)
and rs34065661 (Ala15Gly, p=6.0610
235). Thompson et al [17]
found rs17231520 to be associated with HDL-C in African
Americans in a study of SNPs in CETP. The estimated effects at
these SNPs were 7.81 mg/dl (95% CI: 6.58 to 9.03) per A allele
and 7.71 mg/dl (95% CI: 6.48 to 8.93) per G allele for
rs17231520 and rs34065661, respectively, with a heterogeneity
I
2 of 0% for both. These SNPs showed stronger estimated effects
with HDL-C levels in the PAGE study than the GWAS index SNP
rs3764261 did in the European-descent based Global Lipids
Genetic Consortium meta-analysis [13]. From the PAGE sample
we estimated an effect size of 3.3 (2.64, 4.00) mg/dl for each A
allele in rs3764261 (p=8.7610
222) and an allele frequency of
0.32, compared to 3.4 and 0.32, respectively, given by the Global
Lipids Genetic Consortium. In the PAGE African American
sample the two lead SNPs, rs17231520 and rs34065661, were in
strong LD with each other (r
2=0.998), but both were only weakly
correlated with rs3764261 (r
2=0.16). The MAFs at rs17231520
and rs34065661 were 0.07 for both variants in African Americans,
but the SNPs were very rare or monomorphic in Europeans and
Figure 1. Distribution of minor allele frequencies on the
Metabochip, the Affymetrix 6.0, and the Illumina 1 M. Intervals
are open on the left and closed on the right. The Metabochip MAFs are
calculated from PAGE African American samples, while the Affymetrix
and Illumina GWAS array MAFs are drawn from the HapMap ASW
(African ancestry in Southwest USA) population, a difference not
expected to substantially impact the allele frequency distribution.
doi:10.1371/journal.pone.0035651.g001
Figure 2. Distribution of minor allele frequencies on the
Metabochip, the Affymetrix 6.0, and the Illumina 1 M. Same
comparison as in Figure 1, except that in this figure the minor allele
frequencies on the Metabochip are determined from the Malmo ¨,
Sweden, sample while those on the Affymetrix 6.0 and Illumina 1 M
GWAS arrays are determined from the HapMap CEU sample.
doi:10.1371/journal.pone.0035651.g002
Table 1. Coverage of 2 Metabochip regions by SNPs on the
Illumina 1 M GWAS array.
Maximum r
2 with Illumina 1 M
array SNP CELSR2/PSRC1/SORT1 CETP
[0, 0.50] 105 76
(0.50, 0.99] 11 2
(0.99, 1.00] 7 4
Illumina 1 M array SNPs on Metabochip 20 16
Total 143 98
Linkage disequilibrium was calculated in ASW (African ancestry in Southwest
USA). The CELSR2/PSRC1/SORT1 region refers here to the 40 kb region shown in
Figure 3. The CETP region here refers to the 30 kb region shown in Figure 4.
Counts in the table refer to polymorphic SNPs on the Metabochip that passed
quality control.
doi:10.1371/journal.pone.0035651.t001
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0.0002 for rs34065661; 1000 Genomes Project EUR: MAF=0 for
rs17231520 and MAF=0.002 for rs34065661; 1000 Genomes
Project ASN: MAF=0 for both SNPs). When conditioned on
rs17231520, the strongest remaining HDL-C-associated SNP in
PAGE was rs17231506 (p=4.0610
215 with conditioning while
p=3.2610
210 without conditioning), which showed moderate LD
with the GWAS index SNP rs3764261 (r
2=0.372, p for
rs17231506 conditional on rs3764261=0.79). Although an
argument for independence via a conditioning analysis is not at
all definitive [18], these data are consistent with the presence of
two independent susceptibility signals for HDL-C at this locus in
African Americans, one of which (rs17231506/rs3764261) is
shared with European Americans.
Discussion
Published GWA studies have been predominantly conducted in
European-descent populations [2]; the degree to which GWAS
arrays (along with imputation using HapMap or 1000 Genomes
data) will adequately capture common genetic variants that
influence complex traits in ancestrally diverse populations remains
to be fully determined. The difficulty in generalizing results from
European-descent GWAS to other populations, particularly
African Americans, is consistent with the belief that SNPs on
GWAS arrays do not generally represent causal or functional
SNPs. Because LD patterns differ across populations, tag SNPs
genotyped in populations of non-European ancestry may not
capture the associations observed in European-ancestry popula-
tions. Genotyping with large-scale custom array platforms like the
Metabochip provides an opportunity 1) to test for generalization of
previous GWAS identified SNPs across ancestrally diverse
populations, 2) to fine map the loci, and 3) to possibly identify
additional variants that independently associate with these traits
[19].
By design, the Metabochip provides a greater depth of
coverage, both for overall SNP density and for rare SNPs, in
specific targeted regions of the genome than the Affymetrix 6.0 or
Illumina 1 M arrays. This greater depth of coverage is evident in
both the Malmo ¨ European and PAGE African American
populations. The Metabochip performed well on QC measures
in the PAGE African American sample with 85% to 89% of SNPs
passing QC across the range of MAFs and overall call rates above
97%.
To demonstrate the utility of the fine mapping approach, we
assessed two well-known loci. At the CELSR2/PSRC1/SORT1
locus on chromosome 1, Teslovich and colleagues have reported a
strong association of LDL-C with rs629301 and several nearby
SNPs [13]. In contrast, Lettre and colleagues [16] demonstrated
the strongest association in African-descent populations of LDL-C
in this locus with rs12740374, consistent with our findings.
Musunuru and colleagues [20] conducted a series of human in vitro
and in vivo experiments demonstrating that this common
noncoding variant rs12740374 creates a transcription factor
binding site that alters the hepatic expression of SORT1, thereby
identifying a functional variant at the CELSR2/PSRC1/SORT1
locus. Figure 3A demonstrates that several nearby SNPs are both
highly significant and in high LD in European-descent popula-
tions. However, because of this high LD, it is difficult to discern if
any of these SNPs is a true causal variant. Figure 3B, which
includes additional data on fine-mapping SNPs in an African
American sample, suggests that in these subjects a true causal
variant can be pinpointed to a region in high LD with rs12740374.
Thus, the combination of locally high SNP density on the
Metabochip and the less extensive LD in African Americans
allowed us to distinguish rs12740374 from other SNPs that are in
LD in Europeans. These study findings illustrate how fine
mapping in a African Americans can refine a GWAS signal and,
in this case, uncover a putative functional variant.
Similarly, our findings at the CETP locus on chromosome 16,
associated with HDL-C, demonstrate the value of high-density
genotyping to identify putatively functional alleles that are not
present on GWA arrays. In this case, rs17231520, which showed
Figure 3. Regional association plots for LDL-C near the CELSR2/
PSRC1/SORT1 locus. The LDL-C association signal near the CELSR2/
PSRC1/SORT1 locus is narrower in African Americans than Europeans. (A)
Association results from European-ancestry samples [13] colored by LD
(r
2) in CEU with rs12740374. (B) Association results in African Americans
from PAGE colored by LD (r
2) in the same sample with rs12740374; (C)
The same association results as in (B) but colored by their correlation (r
2)
in the Malmo ¨, Sweden, sample [32] with rs12740374. Positions shown
are based on hg18. Recombination rate shown is based jointly on the
CEU, YRI and JPT+CHB HapMap samples [38].
doi:10.1371/journal.pone.0035651.g003
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is located in the CETP promoter or 59 UTR of different isoforms
of the gene [21]. This variant, described previously to be
associated with HDL-C in African Americans [17], resides in an
SP1/SP3 binding site and has been shown to influence gene
transcriptional activity and CETP protein function. Although
Polyphen-2 [22] predicts that the non-synonymous SNP
rs34065661 (Ala15Gly), our second most significantly associated
SNP at this locus, would have minimal adverse consequences on
protein structure and function, this structural change may have a
biological effect (and, of course, prediction tools are imperfect). As
one of the residues forming the signal peptide that directs transport
of the CETP protein into the lipid membrane, the variant could
affect CETP localization. Neither rs17231520 not rs34065661 is
present on the Affymetrix 6.0 or Illumina 1 M arrays, nor are any
proxies with r
2.0.65 according to the proxy-SNP identification
tool SNAP [23] (in either CEU and YRI based on 1000 Genomes
Pilot 1 data; the SNPs are not in HapMap 3 Release 2). The two
SNPs can, however, be moderately well imputed from 1000
Genomes Phase I v2 data (Rsq=0.79 for both), suggesting that
even in African Americans these lead associations would be found
by a GWAS at best only via imputation. Taken together, our
findings suggest that the high-density genotyping in the Meta-
bochip allowed detection at an already established locus of a
presumably functional SNP that appears to be specific to recent
African descent populations, given MAFs of 0.07 in African
Americans but near 0 in Europeans and Asians. Further work may
identify additional functional variants at CETP and their relative
contributions in other populations.
An alternative to genotyping with the Metabochip would be to
impute genotypes determined using a GWAS array and a 1000
Genomes reference panel [24]. Doing so requires GWAS array
genotypes, of course, and concerns have been raised about the
sensitivity of association results in imputed rare alleles [25]. An
advantage would be that the imputed SNPs would not be limited
to selected regions on the genome. Imputation from GWAS
genotypes to Metabochip SNP genotypes is discussed in Liu et al
[26].
In summary, our results demonstrate the feasibility of using the
Metabochip and the content revealed in the 1000 Genomes
Project to generalize GWAS signals initially discovered in
European-descent populations to African Americans from multiple
sites in the PAGE study. We expect this custom genotyping
approach to point to additional underlying functional variants
once it is applied to a diverse set of populations. Future studies are
expected to incorporate a combination of approaches, including
GWAS and sequencing, to explain the heritable component of
complex traits. In the meantime, the wide-scale application of
targeted custom genotyping strategies such as the Metabochip is
clearly warranted and cost-effective.
Materials and Methods
Study Populations
The PAGE study consists of four study sites and a Coordinating
Center [8]. The four study sites comprise large, diverse
population-based studies: the Epidemiologic Architecture for
Genes Linked to Environment (EAGLE), which accesses three
National Health and Nutrition Examination Surveys; the
Multiethnic Cohort (MEC); the Women’s Health Initiative
(WHI); and Causal Variants Across Life Course (CALiCo), a
collection of cardiovascular cohorts including the Atherosclerosis
Risk in Communities Study (ARIC). The PAGE Metabochip Pilot
Study was limited to African American participants from ARIC
[9], n=3,663, MEC [10], n=458, and WHI [11], n=2,120, for a
total of 6,241 individuals.
Brief Description of the Metabochip Content
The design of the Metabochip is fully described by Voight et al
(in preparation). Approximately 33% of the Metabochip SNPs
consist of replication targets and 62% are located in fine mapping
regions; the other 5% serve a variety of purposes such as CNV
tagging, gender assessment, and coverage of the HLA region.
SNPs identified in the 1000 Genomes Project Pilot 1 [4] make up
about 60% of the Metabochip SNPs. The fine mapping targets
focus on loci that have achieved genome-wide significance for one
or more metabolic and atherosclerotic-cardiovascular traits,
including type 2 diabetes, fasting glucose and insulin, coronary
artery disease/myocardial infarction, LDL-C, HDL-C, triglycer-
ides, body mass index, waist-to-hip ratio, systolic blood pressure,
Figure 4. Regional association plot for HDL-C results from PAGE in African Americans near the CETP locus. SNPs are colored by their LD
(r
2) in the same sample with rs17231520.
doi:10.1371/journal.pone.0035651.g004
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the fine mapping regions varies according to the priorities of the
Metabochip design group with a median density of one SNP per
370 bases in these regions. A total of 257 loci were selected for fine
mapping with the surrounding regions covering a total of
45.52 Mb after accounting for overlaps (14.17 Mb for the densest
fine mapping regions). More details can be found at http://www.
sph.umich.edu/csg/kang/MetaboChip/
Genotyping and Quality Control Assessment
We genotyped samples at the Human Genetics Center of the
University of Texas-Houston, the University of Southern Califor-
nia Genomics Core, and the Translational Genomics Research
Institute (TGen) for the ARIC, MEC, and WHI cohorts,
respectively. Each center followed the manufacturer’s recommen-
dation (Illumina, Inc.) and at a minimum assessed standard quality
controls procedures (e.g., intra- and inter-batch controls, blinded
duplicates) as well as those provided by the manufacturer. Each
center also genotyped 90 HapMap YRI (Yoruba in Ibadan,
Nigeria) samples to facilitate cross-study quality control (QC). To
reduce possible batch effects caused by separate genotyping
centers, we called genotypes separately for each study at the PAGE
Coordinating Center under a common protocol, using GenomeS-
tudio with the GenCall 2.0 algorithm (Illumina Inc., San Diego,
CA). We also called all genotypes with the GenoSNP genotype-
calling algorithm [12], given that the Metabochip includes SNPs
with much lower minor allele frequencies (MAFs) than are usually
called with GenCall. The GenoSNP algorithm may be more
successful for rare genotypes because it is sample-based, rather
than SNP-based [27]. Genotypes called by GenCall were used in
analyses, but discordance between the two methods was used as a
QC filter. The QC criteria, including thresholds, for SNPs are
described in Supporting Information Table S3. QC statistics were
calculated using GenomeStudio and PLINK [28].
We excluded samples with a call rate below 0.95 or an
inbreeding coefficient (F) above 0.15 from further analysis [29].
Prior to quantitative genetic analyses, we identified related persons
using PLINK by estimating identical-by-descent (IBD) statistics for
all pairs. When apparent first-degree relative pairs were identified,
we selected one individual from each pair by excluding the relative
with a lower call rate from further analysis. We determined
principal components of ancestry using EIGENSOFT [30,31] and
excluded apparent ancestral outliers from further analysis as
described in the Supporting Information S1.
LD Estimates and Statistical Analysis of Association of
Lipid Levels
To aid in the interpretation of fine mapping results, we
calculated the r
2 linkage disequilibrium statistic in our African
American PAGE Metabochip Pilot Study sample in 500 kb sliding
windows using PLINK. In addition, the Malmo ¨ Diet and Cancer
Study [32] provided LD and frequency information (but not
individual-level information or any trait information) on 2,143
control subjects from a Swedish population. We also obtained
allele frequencies from HapMap [33] for ASW (African ancestry in
Southwest USA) and CEU (Northern and Western European
ancestry) samples.
We measured serum HDL-C using standard enzymatic
methods and calculated fasting levels of LDL-C using the
Friedewald equation [34], assigning missing values of LDL-C to
individuals with triglyceride levels greater than 400 mg/dl. As
fewer than 10% of these participants were on lipid-lowering
medications at the time of blood draw, we did not exclude
individuals on such medications in these analyses; we did not
attempt to adjust lipid levels for medicated individuals. In a
previous PAGE study, exclusion of lipid-medicated participants in
the ARIC, MEC, and WHI cohorts did not appreciably alter lipids
association results [35]. We used standard linear regression models
with the first two principal components of ancestry for a global
ancestry adjustment and with age and sex as covariates. We
encoded SNPs using the linear additive model and combined
association results across cohorts using an inverse variance fixed
effect meta-analysis approach implemented in METAL [36]. We
also accessed publicly available data from the Global Lipids
Genetic Consortium [13] at http://www.sph.umich.edu/csg/
abecasis/public/lipids2010/ for comparison purposes. We used
LocusZoom [37] for association plots.
Supporting Information
Supporting Information S1 Additional Methods.
(DOC)
Table S1 Number of samples genotyped. ‘‘Failed QC’’ includes
ancestry outliers. ‘‘First degree relative pairs’’ refers to apparent
first-degree relative pairs based on genotypes; one member of each
pair was retained for the analyses.
(DOCX)
Table S2 Quality control outcomes by SNP. ‘‘Technical Quality
Control Failures’’ refers to SNPs failing steps 1–7 in Supporting
Information Table S3.
(DOCX)
Table S3 SNP quality control criteria. GenTrain and cluster
separation scores are Illumina-provided genotype metrics. SNPs
that failed only for GenTrain or cluster separation scores at only
one site and passed a manual inspection were classified as passing.
Otherwise, SNPs failing any criterion for any one study were
classified as failed across PAGE.
(DOCX)
Table S4 Metabochip SNP overall pass rate by minor allele
frequency in the PAGE African American sample. Intervals are
open on the left and closed on the right. The overall pass rate,
including monomorphic SNPs, was 88.7%.
(DOCX)
Acknowledgments
The contents of this paper are solely the responsibility of the authors and
do not necessarily represent the official views of the NIH.
The PAGE consortium thanks the staff and participants of all PAGE
studies for their important contributions. The complete list of PAGE
members can be found at http://www.pagestudy.org.
The authors thank the WHI investigators and staff for their dedication,
and the study participants for making the program possible. A full listing of
WHI investigators can be found at: http://www.whiscience.org/
publications/WHI_investigators_shortlist.pdf.
The authors thank Yun Li for her assistance and advice regarding
genetic imputation.
Author Contributions
Conceived and designed the experiments: CLC LD LAH PB CSC DD
HMK CK LLM JGR FRS TAM CAH UP KEN. Performed the
experiments: PB BC DD CAH UP KEN. Analyzed the data: SB YW TLA
LAH SM JLA PB JH TAM DCC KEN MDF. Contributed reagents/
materials/analysis tools: EB PB CBE NJ CK YL TCM JGR CR FRS BFV
AY KEN. Wrote the paper: SB YW CLC IC TLA LD LAH SM PB NF
FRS BFV TAM KLM CAH UP DCC KEN MDF. Scientific
management: LAH TAM.
Evaluation of the Metabochip in African Americans
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35651References
1. Hindorff LA, MacArthur J, Wise A, Junkins HA, Hall PN, et al. (2011) A
Catalog of Published Genome-Wide Association Studies. Available: http://
www.genome.gov/gwastudies. Accessed 2011 July 1.
2. Rosenberg NA, Huang L, Jewett EM, Szpiech ZA, Jankovic I, et al. (2010)
Genome-wide association studies in diverse populations. Nat Rev Genet 11:
356–366.
3. Teo YY, Small KS, Kwiatkowski DP (2010) Methodological challenges of
genome-wide association analysis in Africa. Nat Rev Genet 11: 149–160.
4. 1000 Genomes Project Consortium (2010) A map of human genome variation
from population-scale sequencing. Nature 467: 1061–1073.
5. Sanna S, Li B, Mulas A, Sidore C, Kang HM, et al. (2011) Fine mapping of five
Loci associated with low-density lipoprotein cholesterol detects variants that
double the explained heritability. PLoS Genet 7: e1002198.
6. Cortes A, Brown MA (2011) Promise and pitfalls of the Immunochip. Arthritis
Res Ther 13: 101.
7. Trynka G, Hunt KA, Bockett NA, Romanos J, Mistry V, et al. (2011) Dense
genotyping identifies and localizes multiple common and rare variant association
signals in celiac disease. Nat Genet 43: 1193–1201.
8. Matise TC, Ambite JL, Buyske S, Carlson CS, Cole SA, et al. (2011) The Next
PAGE in Understanding Complex Traits: Design for the Analysis of Population
Architecture Using Genetics and Epidemiology (PAGE) Study. Am J Epidemiol.
9. The ARIC Investigators (1989) The Atherosclerosis Risk in Communities
(ARIC) Study: design and objectives. American Journal of Epidemiology 129:
687–702.
10. Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, et al. (2000)
A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics.
American Journal of Epidemiology 151: 346–357.
11. The Women’s Health Initiative Study Group (1998) Design of the Women’s
Health Initiative clinical trial and observational study. Controlled Clinical Trials
19: 61–109.
12. Giannoulatou E, Yau C, Colella S, Ragoussis J, Holmes CC (2008) GenoSNP: a
variational Bayes within-sample SNP genotyping algorithm that does not require
a reference population. Bioinformatics 24: 2209–2214.
13. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, et al.
(2010) Biological, clinical and population relevance of 95 loci for blood lipids.
Nature 466: 707–713.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring
inconsistency in meta-analyses. BMJ 327: 557–560.
15. Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, et al. (2009)
Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 41:
56–65.
16. Lettre G, Palmer CD, Young T, Ejebe KG, Allayee H, et al. (2011) Genome-
wide association study of coronary heart disease and its risk factors in 8,090
African Americans: the NHLBI CARe Project. PLoS Genet 7: e1001300.
17. Thompson JF, Lloyd DB, Lira ME, Milos PM (2004) Cholesteryl ester transfer
protein promoter single-nucleotide polymorphisms in Sp1-binding sites affect
transcription and are associated with high-density lipoprotein cholesterol. Clin
Genet 66: 223–228.
18. Wood AR, Hernandez DG, Nalls MA, Yaghootkar H, Gibbs JR, et al. (2011)
Allelic heterogeneity and more detailed analyses of known loci explain additional
phenotypic variation and reveal complex patterns of association. Hum Mol
Genet 20: 4082–4092.
19. Tomlinson IP, Carvajal-Carmona LG, Dobbins SE, Tenesa A, Jones AM, et al.
(2011) Multiple Common Susceptibility Variants near BMP Pathway Loci
GREM1, BMP4, and BMP2 Explain Part of the Missing Heritability of
Colorectal Cancer. PLoS Genet 7: e1002105.
20. Musunuru K, Strong A, Frank-Kamenetsky M, Lee NE, Ahfeldt T, et al. (2010)
From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus.
Nature 466: 714–719.
21. Harrow J, Denoeud F, Frankish A, Reymond A, Chen CK, et al. (2006)
GENCODE: producing a reference annotation for ENCODE. Genome Biol 7
Suppl 1: S4 1–9.
22. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. (2010)
A method and server for predicting damaging missense mutations. Nat Methods
7: 248–249.
23. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O’Donnell CJ, et al. (2008)
SNAP: a web-based tool for identification and annotation of proxy SNPs using
HapMap. Bioinformatics 24: 2938–2939.
24. Sung YJ, Wang L, Rankinen T, Bouchard C, Rao DC (2011) Performance of
Genotype Imputations Using Data from the 1000 Genomes Project. Hum
Hered 73: 18–25.
25. Marchini J, Howie B (2010) Genotype imputation for genome-wide association
studies. Nat Rev Genet 11: 499–511.
26. Liu EY, Buyske S, Aragaki AK, Peters U, Boerwinkle E, et al. (2012) Genotype
Imputation of MetabochipSNPs Using a Study-Specific Reference Panel of
,4,000 Haplotypes in African Americans From the Women’s Health Initiative.
Genetic Epidemiology 36: 107–117.
27. Ritchie ME, Liu R, Carvalho BS, Irizarry RA (2011) Comparing genotyping
algorithms for Illumina’s Infinium whole-genome SNP BeadChips. BMC
Bioinformatics 12: 68.
28. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007)
PLINK: a tool set for whole-genome association and population-based linkage
analyses. American Journal of Human Genetics 81: 559–575.
29. Weale ME (2010) Quality control for genome-wide association studies. Methods
Mol Biol 628: 341–372.
30. Patterson N, Price AL, Reich D (2006) Population structure and eigenanalysis.
PLoS Genetics 2: e190.
31. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, et al. (2006)
Principal components analysis corrects for stratification in genome-wide
association studies. Nature Genetics 38: 904–909.
32. Berglund G, Elmstahl S, Janzon L, Larsson SA (1993) The Malmo Diet and
Cancer Study. Design and feasibility. Journal of internal medicine 233: 45–51.
33. Altshuler DM, Gibbs RA, Peltonen L, Dermitzakis E, Schaffner SF, et al. (2010)
Integrating common and rare genetic variation in diverse human populations.
Nature 467: 52–58.
34. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the
concentration of low-density lipoprotein cholesterol in plasma, without use of
the preparative ultracentrifuge. Clin Chem 18: 499–502.
35. Dumitrescu L, Carty CL, Taylor K, Schumacher FR, Hindorff LA, et al. (2011)
Genetic Determinants of Lipid Traits in Diverse Populations from the
Population Architecture using Genomics and Epidemiology (PAGE) Study.
PLoS Genet 7: e1002138.
36. Willer CJ, Li Y, Abecasis GR (2010) METAL: fast and efficient meta-analysis of
genomewide association scans. Bioinformatics 26: 2190–2191.
37. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, et al. (2010)
LocusZoom: regional visualization of genome-wide association scan results.
Bioinformatics 26: 2336–2337.
38. The International HapMap Consortium (2007) A second generation human
haplotype map of over 3.1 million SNPs. Nature 449: 851–861.
Evaluation of the Metabochip in African Americans
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35651